ExThera Medical Corporation
- Industry
- Medical Device
- Founded Year
- 2007
- Headquarters
- 757 Arnold Dr Ste B, Martinez, California, 94553, United States
- Employee Count
- 27
Key People
- Robert Ward - President and CEO
-
Erin Borger - CEO
Email: [emailprotected]
- Keith McCrea - Vice President of Research and Development and Chief Science Officer
- Vidur Sahney - Chief Operating Officer
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with backgrounds in medical device development and commercialization.
Robert Ward, serving as President and CEO, brings significant expertise in the medical device sector. The presence of multiple seasoned professionals in key roles suggests a strong foundation for strategic decision-making and product development.
- Clinical Need
-
Aspect: Very Strong
Summary: ExThera Medical addresses critical unmet needs in treating severe bloodstream infections.
The Seraph 100 Microbind Affinity Blood Filter is designed to remove a broad range of pathogens from the bloodstream, offering a novel solution for conditions like sepsis and COVID-19. This innovation meets a significant clinical demand for effective treatments in these areas.
- Competition
-
Aspect: First mover
Summary: ExThera Medical appears to be a pioneer in extracorporeal blood filtration for pathogen removal.
As an innovator in this space, ExThera Medical has the advantage of setting industry standards but may also face hurdles in educating the market and establishing trust in new treatment modalities.
- Technical Challenge
-
Aspect: Predictable
Summary: The technology involves established principles of blood filtration and pathogen removal.
Utilizing adsorption techniques to remove pathogens from the bloodstream is a concept grounded in existing medical knowledge, suggesting a manageable path through technical development and regulatory approval.
- Patent
-
Aspect: Very Strong
Summary: ExThera Medical holds robust intellectual property rights for its technologies.
The company's patents cover key aspects of its blood filtration devices, providing a barrier to entry for competitors and securing its market position.
- Financing
-
Aspect: Well-funded
Summary: The company has secured substantial funding to support its operations and growth.
With total funding of approximately $54.6 million from multiple investors, ExThera Medical has the financial resources necessary to advance its product pipeline and commercial strategies.
- Regulatory
-
Aspect: 510k/PMA
Summary: The Seraph 100 has obtained CE Mark and FDA Emergency Use Authorization.
Achieving CE Mark certification in the EU and FDA EUA in the U.S. demonstrates compliance with stringent regulatory standards, enabling the company to market its products in key regions.
Opportunity Rollup
- Odds of Success
- 3.2
- Peak Market Share
- 3.75
- Segment CAGR
- 5.4%
- Market Segment
- Medical Devices
- Market Sub Segment
- Bloodstream Infection Treatment Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.19 |
| 2 | 0.56 |
| 3 | 1.31 |
| 4 | 2.62 |
| 5 | 3.75 |
Key Takeaway
ExThera Medical is well-positioned to address critical needs in bloodstream infection treatment with its innovative Seraph 100 device, supported by a strong team and substantial funding.